Questcor has been beset by short sellers -- over half its float is sold short -- who cite a myriad of issues from reimbursement pressure for its flagship product Achthar to government inquiries and potential competition from overseas.
Well, scratch one concern off the list. Questcor just struck a deal to acquire Novartis drug Synacthen. Shares popped 15% yesterday and tacked on an additional 7% in gains today.
In this video, health-care analyst David Williamson discusses the deal in further detail and the implications for Questcor investors.
Follow David on Twitter @MotleyDavid.
